Lung macrophage defense responses during suramin-induced lysosomal dysfunction

Glenn A. Warr, George J. Jakab

Research output: Contribution to journalArticle

Abstract

Lysosomes form an integral part of the degradative mechanisms of the phagocytic cells. Mice were injected with suramin, a lysosomotrophic drug, to investigate the effects of lysosomal pathology on the cell biology and in situ bactericidal activity of the pulmonary macrophage. Treatment with suramin resulted in marked alterations in the cell biology of the macrophage: (i) increased vacuolization and protein content, (ii) suppressed intracellular phagosome-lysosome fusion, (iii) decreased activity of the lysosomal enzymes β-glucuronidase and N-acetyl-glucosaminidase, and (iv) enhanced exocytosis of acid phosphatase during phagocytosis. Addition of suramin, in vitro, to cell lysates resulted in a reduction in the catalytic activities of acid phosphatase, β-glucuronidase, and N-acetyl-glucosaminidase; thereby suggesting that selective interaction, in vivo, between suramin and lysosomes containing β-glucuronidase and N-acetyl-glucosaminidase may have occurred. Plasma membrane 5′-nucleotide phosphodiesterase activity was increased in macrophages recovered from suramin-treated animals. Although the "resting-state" reduction of nitroblue tetrazolium (NBT) was lower in these macrophages, cells stimulated by a phagocytic challenge demonstrated normal increases in NBT reduction. Phagocytosis, in vitro, and pulmonary bactericidal activity were not altered. These data demonstrate that suramin altered numerous aspects of the phagocyte's lysosomal system. Despite these changes in the cell biology of the pulmonary macrophage, the cell's defense functions were not reduced.

Original languageEnglish (US)
Pages (from-to)193-207
Number of pages15
JournalExperimental and Molecular Pathology
Volume38
Issue number2
DOIs
StatePublished - 1983

Fingerprint

Suramin
Macrophages
Cytology
Hexosaminidases
Lung
Glucuronidase
Lysosomes
Cell Biology
Nitroblue Tetrazolium
Alveolar Macrophages
Phagocytes
Acid Phosphatase
Phagocytosis
Type 5 Cyclic Nucleotide Phosphodiesterases
Phagosomes
Exocytosis
Phosphoric Diester Hydrolases
Pathology
Cell membranes
Catalyst activity

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Pathology and Forensic Medicine

Cite this

Lung macrophage defense responses during suramin-induced lysosomal dysfunction. / Warr, Glenn A.; Jakab, George J.

In: Experimental and Molecular Pathology, Vol. 38, No. 2, 1983, p. 193-207.

Research output: Contribution to journalArticle

Warr, Glenn A. ; Jakab, George J. / Lung macrophage defense responses during suramin-induced lysosomal dysfunction. In: Experimental and Molecular Pathology. 1983 ; Vol. 38, No. 2. pp. 193-207.
@article{34009d6d0e744a82851fe2efc193586b,
title = "Lung macrophage defense responses during suramin-induced lysosomal dysfunction",
abstract = "Lysosomes form an integral part of the degradative mechanisms of the phagocytic cells. Mice were injected with suramin, a lysosomotrophic drug, to investigate the effects of lysosomal pathology on the cell biology and in situ bactericidal activity of the pulmonary macrophage. Treatment with suramin resulted in marked alterations in the cell biology of the macrophage: (i) increased vacuolization and protein content, (ii) suppressed intracellular phagosome-lysosome fusion, (iii) decreased activity of the lysosomal enzymes β-glucuronidase and N-acetyl-glucosaminidase, and (iv) enhanced exocytosis of acid phosphatase during phagocytosis. Addition of suramin, in vitro, to cell lysates resulted in a reduction in the catalytic activities of acid phosphatase, β-glucuronidase, and N-acetyl-glucosaminidase; thereby suggesting that selective interaction, in vivo, between suramin and lysosomes containing β-glucuronidase and N-acetyl-glucosaminidase may have occurred. Plasma membrane 5′-nucleotide phosphodiesterase activity was increased in macrophages recovered from suramin-treated animals. Although the {"}resting-state{"} reduction of nitroblue tetrazolium (NBT) was lower in these macrophages, cells stimulated by a phagocytic challenge demonstrated normal increases in NBT reduction. Phagocytosis, in vitro, and pulmonary bactericidal activity were not altered. These data demonstrate that suramin altered numerous aspects of the phagocyte's lysosomal system. Despite these changes in the cell biology of the pulmonary macrophage, the cell's defense functions were not reduced.",
author = "Warr, {Glenn A.} and Jakab, {George J.}",
year = "1983",
doi = "10.1016/0014-4800(83)90085-0",
language = "English (US)",
volume = "38",
pages = "193--207",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lung macrophage defense responses during suramin-induced lysosomal dysfunction

AU - Warr, Glenn A.

AU - Jakab, George J.

PY - 1983

Y1 - 1983

N2 - Lysosomes form an integral part of the degradative mechanisms of the phagocytic cells. Mice were injected with suramin, a lysosomotrophic drug, to investigate the effects of lysosomal pathology on the cell biology and in situ bactericidal activity of the pulmonary macrophage. Treatment with suramin resulted in marked alterations in the cell biology of the macrophage: (i) increased vacuolization and protein content, (ii) suppressed intracellular phagosome-lysosome fusion, (iii) decreased activity of the lysosomal enzymes β-glucuronidase and N-acetyl-glucosaminidase, and (iv) enhanced exocytosis of acid phosphatase during phagocytosis. Addition of suramin, in vitro, to cell lysates resulted in a reduction in the catalytic activities of acid phosphatase, β-glucuronidase, and N-acetyl-glucosaminidase; thereby suggesting that selective interaction, in vivo, between suramin and lysosomes containing β-glucuronidase and N-acetyl-glucosaminidase may have occurred. Plasma membrane 5′-nucleotide phosphodiesterase activity was increased in macrophages recovered from suramin-treated animals. Although the "resting-state" reduction of nitroblue tetrazolium (NBT) was lower in these macrophages, cells stimulated by a phagocytic challenge demonstrated normal increases in NBT reduction. Phagocytosis, in vitro, and pulmonary bactericidal activity were not altered. These data demonstrate that suramin altered numerous aspects of the phagocyte's lysosomal system. Despite these changes in the cell biology of the pulmonary macrophage, the cell's defense functions were not reduced.

AB - Lysosomes form an integral part of the degradative mechanisms of the phagocytic cells. Mice were injected with suramin, a lysosomotrophic drug, to investigate the effects of lysosomal pathology on the cell biology and in situ bactericidal activity of the pulmonary macrophage. Treatment with suramin resulted in marked alterations in the cell biology of the macrophage: (i) increased vacuolization and protein content, (ii) suppressed intracellular phagosome-lysosome fusion, (iii) decreased activity of the lysosomal enzymes β-glucuronidase and N-acetyl-glucosaminidase, and (iv) enhanced exocytosis of acid phosphatase during phagocytosis. Addition of suramin, in vitro, to cell lysates resulted in a reduction in the catalytic activities of acid phosphatase, β-glucuronidase, and N-acetyl-glucosaminidase; thereby suggesting that selective interaction, in vivo, between suramin and lysosomes containing β-glucuronidase and N-acetyl-glucosaminidase may have occurred. Plasma membrane 5′-nucleotide phosphodiesterase activity was increased in macrophages recovered from suramin-treated animals. Although the "resting-state" reduction of nitroblue tetrazolium (NBT) was lower in these macrophages, cells stimulated by a phagocytic challenge demonstrated normal increases in NBT reduction. Phagocytosis, in vitro, and pulmonary bactericidal activity were not altered. These data demonstrate that suramin altered numerous aspects of the phagocyte's lysosomal system. Despite these changes in the cell biology of the pulmonary macrophage, the cell's defense functions were not reduced.

UR - http://www.scopus.com/inward/record.url?scp=0020622163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020622163&partnerID=8YFLogxK

U2 - 10.1016/0014-4800(83)90085-0

DO - 10.1016/0014-4800(83)90085-0

M3 - Article

VL - 38

SP - 193

EP - 207

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 2

ER -